Research Article
Biocompatibility Profile of a Unique Dual-Biomaterial Hydrogel-Based Medical Device for Intraarticular Use in Osteoarthritis
Issue:
Volume 10, Issue 1, June 2026
Pages:
1-16
Received:
17 February 2026
Accepted:
28 February 2026
Published:
10 March 2026
Abstract: Hydrogel OA 2% is a dual-biomaterial viscoelastic implant developed for intra-articular treatment of osteoarthritis (OA). It consists of hydrolyzed bovine bone protein crosslinked with a carbohydrate, providing mechanical support and joint lubrication while maintaining biocompatibility. This study evaluated its preclinical safety in accordance with ISO 10993 and OECD Good Laboratory Practice (GLP) guidelines. Hydrogel OA 2% underwent cytotoxicity (L-929 fibroblast assay), genotoxicity (Ames and micronucleus), sensitization (guinea pig maximization), pyrogenicity (rabbit pyrogen), acute and 4-, 13-, and 26-week systemic toxicity studies (mice and rats), and intra-articular injection studies in rabbits. Histopathological and cytopathological assessments were performed at weeks 1, 4, 13, and 26 and compared with a hylan-based control gel and saline. No cytotoxic, genotoxic, sensitizing, pyrogenic, or systemic toxic effects were observed. Intra-articular administration induced minimal local reactions, with transient low-grade inflammation at week 4 resolving by week 13, where normal synovial and cartilage architecture was restored. Progressive phagocytic degradation resulted in near-complete material clearance by week 26 without pathological findings in lymph nodes or systemic organs. Chemical characterization and toxicological risk assessment further confirmed negligible biological risk.
Abstract: Hydrogel OA 2% is a dual-biomaterial viscoelastic implant developed for intra-articular treatment of osteoarthritis (OA). It consists of hydrolyzed bovine bone protein crosslinked with a carbohydrate, providing mechanical support and joint lubrication while maintaining biocompatibility. This study evaluated its preclinical safety in accordance with...
Show More
Research Article
Designing the Perfect Microcapsule: Synthetic Hydrogel Selection for Single-Cell Therapeutic Delivery and
Single-Cell Sequencing
Kriti Gorisaria*
Issue:
Volume 10, Issue 1, June 2026
Pages:
17-22
Received:
30 July 2026
Accepted:
22 August 2026
Published:
16 November 2026
DOI:
10.11648/j.jb.20261001.12
Downloads:
Views:
Abstract: The encapsulation of individual mammalian and bacterial cells within protective hydrogel microenvironments has become a transformative approach in regenerative medicine, single-cell transcriptomics, and localized therapy. Although the core principles of hydrogel design particularly the need for extracellular matrix (ECM) mimicry and cytocompatibility are well understood, practical implementation remains challenging due to the vast array of synthetic polymers available. Researchers face critical trade-offs: rapid gelation versus mechanical strength, covalent stability versus cell-mediated degradation, and generic encapsulation versus bioactive functionalization. This review systematically compares three major synthetic hydrogel platforms engineered for single-cell encapsulation, examining their crosslinking mechanisms, mechanical properties, biofunctionalization strategies, and optimal applications. We first evaluate high-performance click-chemistry hydrogels, such as thiol-maleimide and thiol-acrylate PEG systems. These achieve excellent cell viability under mild conditions, making them ideal for preserving transcriptomic integrity in single-cell ribonucleic acid (RNA) sequencing and handling sensitive cell lines like Human Embryonic Kidney (HEK293) and primary macrophages. However, their reliance on precise stoichiometry and limited long-term mechanical stability restrict them primarily to short-term assays. Next, we discuss polyisocyanide (PIC) hydrogels, which undergo physical thermoresponsive gelation and form fibrous architectures that closely mimic collagen. These systems excel in supporting adherent cells such as mesenchymal stem cells, Schwann cells, and hepatocytes. Biofunctionalization via strain-promoted azide-alkyne cycloaddition (SPAAC) with arginine–glycine–aspartic acid (RGD peptides) or growth factor immobilization enables sustained signalling for up to four weeks. Emerging PIC composites with nanoparticles offer near-infrared responsiveness for reversible mechanical tuning, enabling studies of mechanosensitive ion channels (Piezo1 and TRPV4), albeit with increased fabrication complexity. Finally, we critically assess photopolymerized poly (ethylene glycol) (PEG) systems. Conventional PEG diacrylate (PEGDA) suffers from ultraviolet (UV)-induced cytotoxicity and oxygen inhibition, whereas thiol-ene PEG norbornene (PEGNB) offers superior oxygen tolerance and cytocompatibility for extended processing. Disulfide-modified degradable PEGDA (dPEGDA) introduces cell-triggered degradation via glutathione-dependent cleavage, eliminating the need for external stimuli in transplantation. A central feature of this review is a practical decision matrix mapping each hydrogel to its optimal use: thiol-maleimide for transcriptomics, PIC for long-term extracellular matrix (ECM)-mimetic therapy, PEGNB for microfluidic encapsulation, and dPEGDA for scaffold-free tissue integration. We conclude that no universal hydrogel exists; instead, strategic balancing of cytocompatibility, gelation kinetics, mechanical tunability, and degradation profiles enables the design of bespoke microcapsules. This roadmap accelerates the development of next-generation single-cell technologies for both fundamental research and clinical translation.
Abstract: The encapsulation of individual mammalian and bacterial cells within protective hydrogel microenvironments has become a transformative approach in regenerative medicine, single-cell transcriptomics, and localized therapy. Although the core principles of hydrogel design particularly the need for extracellular matrix (ECM) mimicry and cytocompatibili...
Show More